Bilge Mehmet, Tolunay Hatice, Yasar Ayse Saatci, Alemdar Recai, Ali Sina, Kurmus Ozge
Ataturk Education and Research Hospital, Cardiology Department, Ankara, Turkey.
J Heart Valve Dis. 2013 Jan;22(1):89-92.
Transcatheter aortic valve implantation (TAVI) is a promising new technology which is typically used to treat elderly patients with severe aortic stenosis who cannot undergo surgical aortic valve replacement due to high risk factors. This procedure may also be a therapeutic option in particular relatively young cases with severe symptomatic aortic stenosis who are unsuitable candidates for surgery. Clinical experience with TAVI in these patients is very limited due to concerns regarding long-term valve durability. Herein, the case is reported of a 57-year-old man with severe aortic stenosis who presented with decompensated heart failure and successfully underwent transfemoral CoreValve implantation. To the best of the present authors' knowledge, this is the youngest reported patient to have received a CoreValve bioprosthesis to date.
经导管主动脉瓣植入术（TAVI）是一项很有前景的新技术，通常用于治疗因高危因素而无法接受外科主动脉瓣置换术的老年重度主动脉瓣狭窄患者。对于一些患有严重症状性主动脉瓣狭窄但不适合手术的相对年轻患者，该手术也可能是一种治疗选择。由于担心瓣膜的长期耐用性，TAVI在这些患者中的临床经验非常有限。在此，报告一例57岁重度主动脉瓣狭窄男性患者，该患者出现失代偿性心力衰竭，并成功接受了经股动脉CoreValve植入术。据作者所知，这是迄今为止报道的接受CoreValve生物假体植入的最年轻患者。
